ArticleBioImpacts : BI2023

PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy.

Mina Yousefnezhad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.